These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 19816857)

  • 1. Investment in antiviral drugs: a real options approach.
    Attema AE; Lugnér AK; Feenstra TL
    Health Econ; 2010 Oct; 19(10):1240-54. PubMed ID: 19816857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts.
    Postma MJ; Milne G; Nelson EA; Pyenson B; Basili M; Coker R; Oxford J; Garrison LP;
    Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1431-9. PubMed ID: 21133667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitigation of pandemic influenza: review of cost-effectiveness studies.
    Lugnér AK; Postma MJ
    Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):547-58. PubMed ID: 19941432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs.
    Lugnér AK; Postma MJ
    Eur J Public Health; 2009 Oct; 19(5):516-20. PubMed ID: 19692550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for antiviral stockpiling for future influenza pandemics: a global epidemic-economic perspective.
    Carrasco LR; Lee VJ; Chen MI; Matchar DB; Thompson JP; Cook AR
    J R Soc Interface; 2011 Sep; 8(62):1307-13. PubMed ID: 21296791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stockpiling anti-viral drugs for a pandemic: the role of Manufacturer Reserve Programs.
    Harrington JE; Hsu EB
    J Health Econ; 2010 May; 29(3):438-44. PubMed ID: 20236719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economics of stockpiling for an influenza pandemic.
    Dhankhar P; Dasbach EJ; Elbasha EH
    Lancet Infect Dis; 2009 Aug; 9(8):459-60. PubMed ID: 19628168
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cost-effectiveness of prophylaxis and treatment of influenza].
    Rychlik R; Heinen-Kammerer T; Rusche H; Piercy J; Scuffham P; Zöllner Y
    Dtsch Med Wochenschr; 2003 Oct; 128(43):2267-70. PubMed ID: 14574642
    [No Abstract]   [Full Text] [Related]  

  • 9. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
    Rothberg MB; Rose DN
    Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economics of neuraminidase inhibitor stock piling for pandemic influenza, Singapore.
    Lee VJ; Phua KH; Chenm MI; Chow A; Ma S; Goh KT; Leo YS
    Emerg Infect Dis; 2006 Jan; 12(1):95-102. PubMed ID: 16494724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic.
    Lugnér AK; Mylius SD; Wallinga J
    Health Econ; 2010 May; 19(5):518-31. PubMed ID: 19382106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pandemic influenza: is there a corporate duty to prepare?
    McMenamin JP
    Food Drug Law J; 2009; 64(1):69-100. PubMed ID: 19998573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare system cost evaluation of antiviral stockpiling for pandemic influenza preparedness.
    Li Y; Hsu EB; Links JM
    Biosecur Bioterror; 2010 Jun; 8(2):119-28. PubMed ID: 20569054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Willingness-to-pay for a statistical life in the times of a pandemic.
    Gyrd-Hansen D; Halvorsen PA; Kristiansen IS
    Health Econ; 2008 Jan; 17(1):55-66. PubMed ID: 17405185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of combination antiviral therapy in pandemic influenza and stockpiling implications.
    Tsiodras S; Mooney JD; Hatzakis A
    BMJ; 2007 Feb; 334(7588):293-4. PubMed ID: 17289732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty.
    Al MJ; Feenstra TL; Hout BA
    Health Econ; 2005 Jul; 14(7):655-67. PubMed ID: 15678518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buy now, saved later? The critical impact of time-to-pandemic uncertainty on pandemic cost-effectiveness analyses.
    Drake T; Chalabi Z; Coker R
    Health Policy Plan; 2015 Feb; 30(1):100-10. PubMed ID: 24369125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost effectiveness analysis of oseltamivir phosphorus in the treatment of influenza].
    Hu SL; Lin JT; Yu XZ; Wang AX; Zhu JH; Cui DJ; Chen XY; Wang YZ; Wu XD; Gao H
    Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(19):1664-7. PubMed ID: 15569469
    [No Abstract]   [Full Text] [Related]  

  • 20. Using risk assessment, benefit-cost analysis, and real options to implement a precautionary principle.
    Farrow S
    Risk Anal; 2004 Jun; 24(3):727-35. PubMed ID: 15209941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.